Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

US job openings in research and development are plunging as the Trump administration ramps up funding cuts to government ...

Merck KGaA's recent stock dip of 13% might scream trouble, but under the hood, things look remarkably solid. Despite a ...